Clarithromycin: potential increased risk of heart problems or death in patients with heart disease


The FDA ( Food and Drug Administration ) is advising caution before prescribing the antibiotic Clarithromycin ( Biaxin ) to patients with heart disease because of a potential increased risk of heart problems or death that can occur years later.
FDAs recommendation is based on a review of the results of a 10-year follow-up study of patients with coronary heart disease from a large clinical trial that first observed this safety issue.

The large clinical trial, called the CLARICOR trial, observed an unexpected increase in deaths among patients with coronary heart disease who received a two-week course of Clarithromycin that became apparent after patients had been followed for one year or longer.

There is no clear explanation for how Clarithromycin would lead to more deaths than placebo.

Some observational studies also found an increase in deaths or other serious heart-related problems, while others did not.
All the studies had limitations in how they were designed.
Of the six observational studies published to date in patients with or without coronary artery disease, two found evidence of long-term risks from Clarithromycin, and four did not.
Overall, results from the prospective, placebo-controlled CLARICOR trial provide the strongest evidence of the increase in risk compared to the observational study results.
Based on these studies, FDA is unable to determine why the risk of death is greater for patients with heart disease.

As a result, FDA added a new warning about this increased risk of death in patients with heart disease, and advised prescribers to consider using other antibiotics in such patients.
FDA also added the study results to the Clarithromycin drug labels.

Clarithromycin is used to treat many types of infections affecting the skin, ears, sinuses, lungs, and other parts of the body, including Mycobacterium avium complex ( MAC ) infection, a type of lung infection that often affects people with human immunodeficiency virus ( HIV ).
Clarithromycin is not approved to treat heart disease.

Healthcare professionals should be aware of these significant risks and weigh the benefits and risks of Clarithromycin before prescribing it to any patient, particularly in patients with heart disease and even for short periods, and consider using other available antibiotics.
Advise patients with heart disease of the signs and symptoms of cardiovascular problems, regardless of the medical condition for which you are treating them with Clarithromycin. ( Xagena )

Source: FDA, 2018

XagenaMedicine_2018



Indietro

Altri articoli

The nucleoside-modified messenger RNA in COVID-19 mRNA vaccine BNT162b2 is formulated in lipid nanoparticles, which enable delivery of the RNA...


Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was...


Initial preliminary findings from the Papa Giovanni XXIII Hospital sponsored SISCO ( Siltuximab In Serious COVID-19 ) Study, based on...


The FDA ( U.S. Food and Drug Administration ) has expanded the approval of Mavyret ( Glecaprevir and Pibrentasvir )...


Results from the largest study of hepatitis B and C and HIV infection prevalence in cancer patients show an alarmingly...


The FDA ( U.S. Food and Drug Administration ) has approved Dovato ( Dolutegravir and Lamivudine ), as a complete...


The European Commission has granted Marketing Authorisation for Dovato ( Dolutegravir / Lamivudine ) for the treatment of HIV-1 infection...


The results of a study has shown that patients living with HIV and one of a variety of potentially deadly...


Week 48 results from phase III TANGO study were announced. The TANGO study was conducted to assess whether adults living...


The FDA ( U.S. Food and Drug Administration ) has approved Biktarvy ( Bictegravir 50mg / Emtricitabine 200mg / Tenofovir...